Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

• Sara A. Hurvitz,
• Aditya Bardia,
• Kevin Punie,
• Kevin Kalinsky,
• Lisa A. Carey,
• Hope S. Rugo,
• Véronique Diéras,
• See Phan,
• Rosemary Delaney,
• Yanni Zhu,
• Sara M. Tolaney

Affiliations

Sara A. Hurvitz

Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center

Aditya Bardia

Massachusetts General Hospital Cancer Center, Harvard Medical School

Kevin Punie

Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven

Kevin Kalinsky

Winship Cancer Institute, Emory University

Lisa A. Carey

University of North Carolina Lineberger Comprehensive Cancer Center

Hope S. Rugo

University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

Véronique Diéras

Centre Eugène Marquis

See Phan

Gilead Sciences Inc.

Rosemary Delaney

Gilead Sciences Inc.

Yanni Zhu

Gilead Sciences Inc.

Sara M. Tolaney

Dana-Farber Cancer Institute, Harvard Medical School